CLINICAL TRIALS PROFILE FOR VILAZODONE HYDROCHLORIDE

All Clinical Trials for Vilazodone Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00285376 ↗	Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response	Completed	Genaissance Pharmaceuticals	Phase 3	2006-02-01	This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.
NCT00290914 ↗	Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder	Completed	Pharmacology Research Institute	Phase 2	1969-12-31	The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
NCT00644358 ↗	A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)	Completed	Forest Laboratories	Phase 3	2007-12-31	This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.
NCT00683592 ↗	Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)	Completed	Forest Laboratories	Phase 3	2008-03-01	This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria.
NCT01473381 ↗	Safety and Efficacy of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
NCT01473394 ↗	Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.

Clinical Trial Conditions for Vilazodone Hydrochloride

Condition Name

Condition Name for Vilazodone Hydrochloride
Intervention	Trials
Major Depressive Disorder	13
Generalized Anxiety Disorder	3
Depressive Disorder, Major	1
Social Anxiety Disorder	1

Condition MeSH

Condition MeSH for Vilazodone Hydrochloride
Intervention	Trials
Depression	16
Disease	15
Depressive Disorder, Major	15
Depressive Disorder	15

Clinical Trial Locations for Vilazodone Hydrochloride

Trials by Country

Trials by Country for Vilazodone Hydrochloride
Location	Trials
United States	227
Ukraine	5
Serbia	4
Canada	4
Germany	3

Trials by US State

Trials by US State for Vilazodone Hydrochloride
Location	Trials
California	14
Florida	12
Texas	12
New York	11
Tennessee	10

Clinical Trial Progress for Vilazodone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Vilazodone Hydrochloride
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	10
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Vilazodone Hydrochloride
Clinical Trial Phase	Trials
Completed	24
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Vilazodone Hydrochloride

Sponsor Name

Sponsor Name for Vilazodone Hydrochloride
Sponsor	Trials
Forest Laboratories	19
Federal University of São Paulo	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for Vilazodone Hydrochloride
Sponsor	Trials
Other	22
Industry	21
NIH	1